News Sharing
For sharing news, please enter the email address of you and the receiver, then press SEND button.*Mandatory Fields
Receiver*
Enter email addresses, separated by semicolon (;). E.g. a@a.com;b@b.com
Your email address*
 Content Sharing
<Research>CICC Upbeat About GIANT BIOGENE's Mid-to-Long Term Growth Potential; Product Matrix Expansion Expected by 2026
GIANT BIOGENE (02367.HK) announced on Tuesday (3rd) a plan to repurchase no more than 104 million shares (10% of issued shares) and communicate with the capital market regarding st...
Reset
Send
The window will close in 5 seconds
<Research>CICC Upbeat About GIANT BIOGENE's Mid-to-Long Term Growth Potential; Product Matrix Expansion Expected by 2026
Close
Recommend
6
Positive
4
Negative
2
 
SHORT SELL
 
STOCK INFO
aacat by AASTOCKS
Open a new trading account to get NVDA share!

GIANT BIOGENE (02367.HK)  -0.080 (-0.281%)    Short selling $57.25M; Ratio 87.582%   announced on Tuesday (3rd) a plan to repurchase no more than 104 million shares (10% of issued shares) and communicate with the capital market regarding strategies for product matrix expansion, brand operation, and channel development by 2026, according to CICC's research report.

CICC viewed the repurchase as a sign of GIANT BIOGENE management's confidence. Meanwhile, the company maintained solid R&D capabilities, brand recognition, and team cohesion. It could improve its operations with product structure optimization, timely operational strategy tweaks, and the increased volume of its second curve medical aesthetics business. The broker was upbeat about its mid-to-long term growth as a leader in recombinant collagen.

CICC kept an Outperform rating on GIANT BIOGENE but cut its target price by 20% to HKD56.
(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-04-02 16:25.)

AASTOCKS Financial News
Copyright(C) AASTOCKS.com Limited 2000. All rights reserved.
Disclaimer: AASTOCKS.com Ltd, HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the Information provided but do not guarantee its accuracy or reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.